These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

348 related items for PubMed ID: 25480473

  • 1. Efficacy of RECIST and mRECIST criteria as prognostic factors in patients undergoing repeated iodized oil chemoembolization of intermediate stage hepatocellular carcinoma.
    Hyun D, Shin SW, Cho SK, Park KB, Park HS, Choo SW, Do YS, Choo IW, Shin JW, Lim SJ.
    Acta Radiol; 2015 Dec; 56(12):1437-45. PubMed ID: 25480473
    [Abstract] [Full Text] [Related]

  • 2. Radiologic response to transcatheter hepatic arterial chemoembolization and clinical outcomes in patients with hepatocellular carcinoma.
    Kim CJ, Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI, Kim MJ.
    Liver Int; 2014 Feb; 34(2):305-12. PubMed ID: 23890360
    [Abstract] [Full Text] [Related]

  • 3. Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
    Jung ES, Kim JH, Yoon EL, Lee HJ, Lee SJ, Suh SJ, Lee BJ, Seo YS, Yim HJ, Seo TS, Lee CH, Yeon JE, Park JJ, Kim JS, Bak YT, Byun KS.
    J Hepatol; 2013 Jun; 58(6):1181-7. PubMed ID: 23395691
    [Abstract] [Full Text] [Related]

  • 4. Which Criteria Applied in Multi-Phasic CT Can Predict Early Tumor Response in Patients with Hepatocellular Carcinoma Treated Using Conventional TACE: RECIST, mRECIST, EASL or qEASL?
    Zhao Y, Duran R, Bai W, Sahu S, Wang W, Kabus S, Lin M, Han G, Geschwind JF.
    Cardiovasc Intervent Radiol; 2018 Mar; 41(3):433-442. PubMed ID: 29086058
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Rationality and effectiveness of transarterial chemoembolization as an initial treatment for BCLC B stage HBV-related hepatocellular carcinoma.
    Heng-jun G, Yao-jun Z, Min-shan C, Mei-xian C, Jun-ting H, Li X, Lau WY.
    Liver Int; 2014 Apr; 34(4):612-20. PubMed ID: 24028297
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients.
    Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, Matsuyama Y, Nakanuma Y, Kojiro M, Makuuchi M, Yamaoka Y, Liver Cancer Study Group of Japan.
    Gastroenterology; 2006 Aug; 131(2):461-9. PubMed ID: 16890600
    [Abstract] [Full Text] [Related]

  • 15. Nonresectable combined hepatocellular carcinoma and cholangiocarcinoma: analysis of the response and prognostic factors after transcatheter arterial chemoembolization.
    Kim JH, Yoon HK, Ko GY, Gwon DI, Jang CS, Song HY, Shin JH, Sung KB.
    Radiology; 2010 Apr; 255(1):270-7. PubMed ID: 20308463
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of HCC response to locoregional therapy: Validation of MRI-based response criteria versus explant pathology.
    Gordic S, Corcuera-Solano I, Stueck A, Besa C, Argiriadi P, Guniganti P, King M, Kihira S, Babb J, Thung S, Taouli B.
    J Hepatol; 2017 Dec; 67(6):1213-1221. PubMed ID: 28823713
    [Abstract] [Full Text] [Related]

  • 17. Transarterial Radioembolization Following Chemoembolization for Unresectable Hepatocellular Carcinoma: Response Based on Apparent Diffusion Coefficient Change is an Independent Predictor for Survival.
    Klompenhouwer EG, Dresen RC, Verslype C, Laenen A, Bonne L, Vandecaveye V, Maleux G.
    Cardiovasc Intervent Radiol; 2018 Nov; 41(11):1716-1726. PubMed ID: 29872894
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Prospective comparison of prognostic values of modified Response Evaluation Criteria in Solid Tumours with European Association for the Study of the Liver criteria in hepatocellular carcinoma following chemoembolisation.
    Kim BK, Kim KA, Park JY, Ahn SH, Chon CY, Han KH, Kim SU, Kim MJ.
    Eur J Cancer; 2013 Mar; 49(4):826-34. PubMed ID: 22995582
    [Abstract] [Full Text] [Related]

  • 20. The true role of mRECIST guideline: does it really estimate viable tumor or merely improve accuracy in hepatocellular carcinoma response evaluation?
    Liu Q, Li A, Sun S, Luo R, Chen F.
    J BUON; 2014 Mar; 19(2):398-405. PubMed ID: 24965398
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.